<?xml version="1.0" encoding="UTF-8"?>
<table id="PMC6939334/table_5" xmlns="http://www.w3.org/1999/xhtml">
 <caption>
  <label>Table 5</label>
  <p>US FDA-approved human mAbs</p>
 </caption>
 <thead>
  <tr>
   <th colspan="1" rowspan="1" id="0-0-.">No.</th>
   <th colspan="1" rowspan="1" id="0-1-.">Antibody</th>
   <th colspan="1" rowspan="1" id="0-2-.">Brandname</th>
   <th colspan="1" rowspan="1" id="0-3-.">Company</th>
   <th colspan="1" rowspan="1" id="0-4-.">Approval 
    <sup>#</sup>
   </th>
   <th colspan="1" rowspan="1" id="0-5-.">Target</th>
   <th colspan="1" rowspan="1" id="0-6-.">References</th>
   <th colspan="1" rowspan="1" id="0-7-.">Technology</th>
  </tr>
 </thead>
 <tbody>
  <tr>
   <td>1</td>
   <td>Adalimumab</td>
   <td>Humira</td>
   <td>Abbott_Laboratories</td>
   <td>2002</td>
   <td>TNFα</td>
   <td>den Broeder et al. [ 
    <a ref-type="bibr" rid="CR178">178</a>] 
   </td>
   <td>Phage display</td>
  </tr>
  <tr>
   <td>2</td>
   <td>Panitumumab</td>
   <td>Vectibix</td>
   <td>Amgen</td>
   <td>2006</td>
   <td>EGFR</td>
   <td>Tyagi et al. [ 
    <a ref-type="bibr" rid="CR179">179</a>] 
   </td>
   <td>XenoMouse</td>
  </tr>
  <tr>
   <td>3</td>
   <td>Ustekinumab</td>
   <td>Stelara</td>
   <td>Johnson &amp; Johnson</td>
   <td>2009</td>
   <td>IL-12</td>
   <td>Bartlett et al. [ 
    <a ref-type="bibr" rid="CR17">17</a>] 
   </td>
   <td>HuMabMouse</td>
  </tr>
  <tr>
   <td>4</td>
   <td>Canakinumab</td>
   <td>Ilaris</td>
   <td>Novartis</td>
   <td>2009</td>
   <td>IL-1β</td>
   <td>Church et al. [ 
    <a ref-type="bibr" rid="CR18">18</a>] 
   </td>
   <td>HuMabMouse</td>
  </tr>
  <tr>
   <td>5</td>
   <td>Golimumab</td>
   <td>Simponi</td>
   <td>Johnson &amp; Johnson/Merck</td>
   <td>2009</td>
   <td>TNFα</td>
   <td>Zhou et al. [ 
    <a ref-type="bibr" rid="CR19">19</a>] 
   </td>
   <td>HuMabMouse</td>
  </tr>
  <tr>
   <td>6</td>
   <td>Ofatumumab</td>
   <td>Arzerra</td>
   <td>GlaxoSmithKline (Genmab)</td>
   <td>2009</td>
   <td>CD20</td>
   <td>Coiffier et al. [ 
    <a ref-type="bibr" rid="CR20">20</a>] 
   </td>
   <td>HuMabMouse</td>
  </tr>
  <tr>
   <td>7</td>
   <td>Denosumab</td>
   <td>Prolia, Xgeva</td>
   <td>Amgen</td>
   <td>2010</td>
   <td>RANKL</td>
   <td>Reddy et al. [ 
    <a ref-type="bibr" rid="CR21">21</a>] 
   </td>
   <td>XenoMouse</td>
  </tr>
  <tr>
   <td>8</td>
   <td>Belimumab</td>
   <td>Benlysta</td>
   <td>GlaxoSmithKline</td>
   <td>2011</td>
   <td>BCAF</td>
   <td>Ding et al. [ 
    <a ref-type="bibr" rid="CR180">180</a>] 
   </td>
   <td>Phage display</td>
  </tr>
  <tr>
   <td>9</td>
   <td>Ipilimumab</td>
   <td>Yervoy</td>
   <td>Bristol-Myers Squibb</td>
   <td>2011</td>
   <td>CTLA-4</td>
   <td>Morse et al. [ 
    <a ref-type="bibr" rid="CR22">22</a>] 
   </td>
   <td>HuMabMouse</td>
  </tr>
  <tr>
   <td>10</td>
   <td>Ramucirumab</td>
   <td>Cyramza</td>
   <td>Eli Lilly (ImClone)</td>
   <td>2014</td>
   <td>VEGFR2</td>
   <td>Krupitskaya et al. [ 
    <a ref-type="bibr" rid="CR181">181</a>] 
   </td>
   <td>Phage display</td>
  </tr>
  <tr>
   <td>11</td>
   <td>Nivolumab</td>
   <td>Opdivo</td>
   <td>Bristol-Myers Squibb</td>
   <td>2014</td>
   <td>PD-1</td>
   <td>Wolchok et al. [ 
    <a ref-type="bibr" rid="CR23">23</a>] 
   </td>
   <td>HuMabMouse</td>
  </tr>
  <tr>
   <td>12</td>
   <td>Alirocumab</td>
   <td>Praluent</td>
   <td>Sanofi and Regeneron</td>
   <td>2015</td>
   <td>PCSK9</td>
   <td>Roth et al. [ 
    <a ref-type="bibr" rid="CR24">24</a>] 
   </td>
   <td>Veloclmmune Mouse</td>
  </tr>
  <tr>
   <td>13</td>
   <td>Daratumumab</td>
   <td>Darzalex</td>
   <td>Johnson &amp; Johnson (Genmab)</td>
   <td>2015</td>
   <td>CD38</td>
   <td>de Weers et al. [ 
    <a ref-type="bibr" rid="CR25">25</a>] 
   </td>
   <td>HuMabMouse</td>
  </tr>
  <tr>
   <td>14</td>
   <td>Necitumumab</td>
   <td>Portrazza</td>
   <td>Eli Lilly (ImClone)</td>
   <td>2015</td>
   <td>EGFR</td>
   <td>Kuenen et al. [ 
    <a ref-type="bibr" rid="CR182">182</a>] 
   </td>
   <td>Phage display</td>
  </tr>
  <tr>
   <td>15</td>
   <td>Evolocumab</td>
   <td>Repatha</td>
   <td>Amgen</td>
   <td>2015</td>
   <td>PCSK9</td>
   <td>Hirayama et al. [ 
    <a ref-type="bibr" rid="CR26">26</a>] 
   </td>
   <td>XenoMouse</td>
  </tr>
  <tr>
   <td>16</td>
   <td>Secukinumab</td>
   <td>Cosentyx</td>
   <td>Novartis</td>
   <td>2015</td>
   <td>IL-17α</td>
   <td>Chioato et al. [ 
    <a ref-type="bibr" rid="CR27">27</a>] 
   </td>
   <td>XenoMouse</td>
  </tr>
  <tr>
   <td>17</td>
   <td>Olaratumab</td>
   <td>Lartruvo</td>
   <td>Eli Lilly</td>
   <td>2016</td>
   <td>PDGFRα</td>
   <td>Chiorean et al. [ 
    <a ref-type="bibr" rid="CR28">28</a>] 
   </td>
   <td>HuMabMouse</td>
  </tr>
  <tr>
   <td>18</td>
   <td>Atezolizumab</td>
   <td>Tecentriq</td>
   <td>Roche</td>
   <td>2016</td>
   <td>PD-L1</td>
   <td>McDermott et al. [ 
    <a ref-type="bibr" rid="CR183">183</a>] 
   </td>
   <td>Phage display</td>
  </tr>
  <tr>
   <td>19</td>
   <td>Avelumab</td>
   <td>Bavencio</td>
   <td>Pfizer</td>
   <td>2017</td>
   <td>PD-L1</td>
   <td>Boyerinas et al. [ 
    <a ref-type="bibr" rid="CR184">184</a>] 
   </td>
   <td>Phage display</td>
  </tr>
  <tr>
   <td>20</td>
   <td>Brodalumab</td>
   <td>Siliq</td>
   <td>Valeant Pharmaceuticals</td>
   <td>2017</td>
   <td>IL-17R</td>
   <td>Papp et al. [ 
    <a ref-type="bibr" rid="CR29">29</a>] 
   </td>
   <td>XenoMouse</td>
  </tr>
  <tr>
   <td>21</td>
   <td>Dupilumab</td>
   <td>Dupixent</td>
   <td>Sanofi and Regeneron</td>
   <td>2017</td>
   <td>IL-4R</td>
   <td>Wenzel et al. [ 
    <a ref-type="bibr" rid="CR30">30</a>] 
   </td>
   <td>Veloclmmune Mouse</td>
  </tr>
  <tr>
   <td>22</td>
   <td>Durvalumab</td>
   <td>Imfinzi</td>
   <td>Medimmune/AstraZeneca</td>
   <td>2017</td>
   <td>PD-L1</td>
   <td>Antonia et al. [ 
    <a ref-type="bibr" rid="CR31">31</a>] 
   </td>
   <td>XenoMouse</td>
  </tr>
  <tr>
   <td>23</td>
   <td>Guselkumab</td>
   <td>Tremfya</td>
   <td>Jassen Biotech</td>
   <td>2017</td>
   <td>IL-23</td>
   <td>Sofen et al. [ 
    <a ref-type="bibr" rid="CR185">185</a>] 
   </td>
   <td>Phage display</td>
  </tr>
  <tr>
   <td>24</td>
   <td>Sarilumab</td>
   <td>Kevzara</td>
   <td>Sanofi and Regeneron</td>
   <td>2017</td>
   <td>IL-6R</td>
   <td>Huizinga et al. [ 
    <a ref-type="bibr" rid="CR32">32</a>] 
   </td>
   <td>Veloclmmune Mouse</td>
  </tr>
  <tr>
   <td>25</td>
   <td>Erenumab</td>
   <td>Aimovig</td>
   <td>Novartis and Amgen</td>
   <td>2018</td>
   <td>CGRPR</td>
   <td>Tepper et al. [ 
    <a ref-type="bibr" rid="CR33">33</a>] 
   </td>
   <td>XenoMouse</td>
  </tr>
  <tr>
   <td>26</td>
   <td>Cemiplimab</td>
   <td>Libtayo</td>
   <td>Regeneron</td>
   <td>2018</td>
   <td>PD-1</td>
   <td>Migden et al. [ 
    <a ref-type="bibr" rid="CR34">34</a>] 
   </td>
   <td>Veloclmmune Mouse</td>
  </tr>
  <tr>
   <td>27</td>
   <td>Emapalumab</td>
   <td>Gamifant</td>
   <td>NovImmmune</td>
   <td>2018</td>
   <td>IFNγ</td>
   <td>Al-Salama ZT [ 
    <a ref-type="bibr" rid="CR186">186</a>] 
   </td>
   <td>Phage display</td>
  </tr>
  <tr>
   <td>28</td>
   <td>Moxetumomab pasudodox</td>
   <td>Lumoxiti</td>
   <td>MedImmune/AstraZeneca</td>
   <td>2018</td>
   <td>CD22</td>
   <td>Kreitman et al. [ 
    <a ref-type="bibr" rid="CR187">187</a>] 
   </td>
   <td>Phage display</td>
  </tr>
 </tbody>
 <tfoot>
  <p>
   <sup>#</sup>Year of the first US FDA approval 
  </p>
 </tfoot>
</table>
